Figure 1.
Figure 1. Sequence of the proximal CD11a promoter region around the MS7 element and recognition of the MS7 probe by nuclear extracts from lymphoid and myeloid cells. (A) CD11a proximal promoter sequence (–130 to –81) flanking the MS7 element. The oligonucleotides used throughout this paper are shown below the sequence, with mutated nucleotides in lowercase. The positions of the overlapping RUNX-binding site (AML-110) and C/EBP-binding sites (CEBP-100) are indicated. (B) EMSA was performed on the MS7 oligonucleotide probe using nuclear extracts from the indicated lymphoid and myeloid cells. (C) EMSA was carried out on the MS7 oligonucleotide probes using nuclear extracts from U937 cells and in the absence or presence of the indicated unlabeled competitor oligonucleotides (at 100-fold molar excess) or C/EBPα- or C/EBPβ-specific polyclonal antisera. The position of RUNX- or C/EBP-containing complexes is indicated.

Sequence of the proximal CD11a promoter region around the MS7 element and recognition of the MS7 probe by nuclear extracts from lymphoid and myeloid cells. (A) CD11a proximal promoter sequence (–130 to –81) flanking the MS7 element. The oligonucleotides used throughout this paper are shown below the sequence, with mutated nucleotides in lowercase. The positions of the overlapping RUNX-binding site (AML-110) and C/EBP-binding sites (CEBP-100) are indicated. (B) EMSA was performed on the MS7 oligonucleotide probe using nuclear extracts from the indicated lymphoid and myeloid cells. (C) EMSA was carried out on the MS7 oligonucleotide probes using nuclear extracts from U937 cells and in the absence or presence of the indicated unlabeled competitor oligonucleotides (at 100-fold molar excess) or C/EBPα- or C/EBPβ-specific polyclonal antisera. The position of RUNX- or C/EBP-containing complexes is indicated.

Close Modal

or Create an Account

Close Modal
Close Modal